jRCT2051240046进行中（未招募）不适用
Phase 3 Double-blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Biktarvy(R) (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Virologically Suppressed People With HIV-1
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 546
- 主要终点
- Proportion of Participants with HIV-1 RNA >= 50 copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Currently receiving B/F/TAF for at least 6 months prior to screening.
- •If plasma human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) measurements in the last 6 months prior to screening are available, all levels must be < 50 copies/mL.
- •At least one documented HIV-1 RNA level measured between 6 and 12 months (+- 2 months) prior to screening. This and any other HIV-1 RNA measurements documented in this period must be < 50 copies/mL.
- •Plasma HIV-1 RNA levels < 50 copies/mL at screening.
- •No documented or suspected resistance to BIC (including integrase strand-transfer inhibitor resistant (INSTI-R) mutations T66A/I/K, E92G/Q, G118R, F121Y, Y143C/H/R, S147G, Q148H/K/R, N155H/S, or R263K in the integrase gene).
- •No documented or suspected resistance to tenofovir alafenamide (TAF) (TAF; mutations K65R, K65N, K70E, Q151M or T69 insertion, or >= 3 of the following thymidine analog mutations [M41L, D67N, K70R, L210W, T215Y/F, K219Q/E/N/R] in the reverse transcriptase gene).
- •Estimated glomerular filtration rate >= 30 mL/min according to the Cockcroft-Gault formula for creatinine clearance.
排除标准
- •Positive serum pregnancy test or pregnant at screening or a positive pregnancy test prior to Day 1 randomization.
- •Breastfeeding (nursing).
- •Prior use of, or exposure to, LEN.
- •Active, serious infections (other than HIV-1) requiring parenteral therapy < 30 days prior to randomization.
- •Active tuberculosis infection.
- •Acute hepatitis < 30 days before randomization.
- •Chronic hepatitis B virus (HBV) infection, as determined by either:
- •Positive HBV surface antigen and negative HBV surface antibody, regardless of HBV core antibody status, at the screening visit.
- •Positive HBV core antibody and negative HBV surface antibody, regardless of HBV surface antigen status, at the screening visit.
- •Known hypersensitivity to the study drug, its metabolites, or any formulation excipient.
- •History of or current clinical decompensated liver cirrhosis (eg, ascites, encephalopathy, or variceal bleeding).
- •Abnormal electrocardiogram (ECG) at the screening visit that is clinically significant as determined by the investigator.
- •Active malignancy requiring acute systemic therapy.
- •Any of the following laboratory values at screening:
- •Alanine aminotransferase > 5 x upper limit of normal (ULN).
- •Direct bilirubin > 1.5 x ULN.
- •Platelets < 50,000/mm^
- •Hemoglobin < 8.0 g/dL.
- •Requirement for ongoing therapy with or prior use of any prohibited medications listed in the protocol.
- •Participation or planned participation in any other clinical study (including observational studies) without prior approval from the sponsor.
- •Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the participant unsuitable for the study or unable to comply with dosing requirements.
- •Note: Other protocol defined Inclusion/Exclusion criteria may apply.
结局指标
主要结局
Proportion of Participants with HIV-1 RNA >= 50 copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
时间窗: Week 48
Proportion of Participants with HIV-1 RNA >= 50 copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
次要结局
未报告次要终点
研究者
相似试验
招募中
不适用
Evaluation of the efficacy of glecaprevir and pibrentasvir for Japanese hepatitis C patients: a prospective study in real life settings.cirrhotic and non cirrhotic patients with chronic hepatitis C virusJPRN-UMIN000031664Toranomon Hospital350
已完成
不适用
Comparison of Levobupivacaine versus Bupivacaine in Fascia Iliaca Compartment Block (FICB) [A type of anaesthesia] for Postoperative Pain Management in Surgeries for Hip FracturesCTRI/2018/01/011464Maharana Bhupal Government Hospital45
尚未招募
3 期
Comparison the effectiveness of bupivacaine in spinal anesthesia with meperidine and sufentanil in patients undergoing elective cesarean section.Spinal anesthesia.Other complications of spinal and epidural anesthesia during pregnancyO29.5IRCT20191010045048N1Zahedan University of Medical Sciences135
已完成
4 期
A comparison of the efficacy of levobupivacaine 0,125%, ropivacaine 0,125% and ropivacaine 0,2%, all combined with sufentanil 0.5 micrograms/mL, in patient-controlled epidural analgesia after hysterectomy under combined epidural and general anesthesiahysterectomyremoval of uterus10029903NL-OMON30436Academisch Medisch Centrum63
进行中（未招募）
不适用
A comparison of the efficacy of levobupivacaine 0,125%, ropivacaine 0,125% and ropivacaine 0,2%, all combined with sufentanil 0.5 micrograms/mL, in patient-controlled epidural analgesia after hysterectomy under combined epidural and general anesthesiaEUCTR2007-000202-75-NLeids Universitair Medisch Centrum63